Grant: Project Grant - PA: Pandemic Preparedness and Health Emergencies Research
University of Toronto
$100,000.00
Exploration of variable lymphocyte receptor antibodies as alternative for antibiotic treatment in the gastrointestinal tract
EF 2025-26
Résumé
The development of antibiotic reagents ranks among the most important accomplishments of biomedical research. However, increasing frequencies of antimicrobial resistance represents a growing risk to public health and requires the development of alternatives to conventional antibiotic treatment regimens. Antibodies are proteins secreted by cells of the immune system that are tasked to recognize and inactivate invading pathogens. They have also been successfully used in the treatment of various cancers and autoimmune disorders. However, antibodies cannot be readily used in the challenging environment of the gastrointestinal tract. The non-conventional variable lymphocyte receptor (VLR) B antibodies of the evolutionarily distant sea lamprey use a different protein architecture compared to conventional antibodies. They recognize their targets with equal specificity and are resistant to the acidic conditions found in the stomach or to digestive enzymes of the intestinal tract. These features suggest that VLRB antibodies may be ideally suited to target bacterial pathogens in the gastrointestinal tract. In this research application, we propose to explore the applicability of VLRB antibodies (i) to target pathogenic bacteria and (ii) to target factors of the immune system in response to pathogenic bacteria challenge that promote inflammation. The results from this study will provide information on the suitability of VLRB antibodies as alternative to antibiotic treatment. They will determine the feasibility of VLRB antibody-based targeting of pathogenic bacteria or factors promoting inflammation in the stomach or intestines with the aim to develop VLRB antibodies as novel class of oral therapeutic.
Programme
Project Grant - PA: Pandemic Preparedness and Health Emergencies Research
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
554773
Name
Ehrhardt Rudolf A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Microbiology & Infectious Diseases
Projecttitle
Exploration of variable lymphocyte receptor antibodies as alternative for antibiotic treatment in the gastrointestinal tract
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Pandemic Preparedness and Health Emergencies Research
Keyworddelim
Antibodies; Cytokine; Evolution; Jawless Vertebrates; Microbiome; Variable Lymphocyte Receptor; Virulence Factor
Abstract
The development of antibiotic reagents ranks among the most important accomplishments of biomedical research. However, increasing frequencies of antimicrobial resistance represents a growing risk to public health and requires the development of alternatives to conventional antibiotic treatment regimens. Antibodies are proteins secreted by cells of the immune system that are tasked to recognize and inactivate invading pathogens. They have also been successfully used in the treatment of various cancers and autoimmune disorders. However, antibodies cannot be readily used in the challenging environment of the gastrointestinal tract. The non-conventional variable lymphocyte receptor (VLR) B antibodies of the evolutionarily distant sea lamprey use a different protein architecture compared to conventional antibodies. They recognize their targets with equal specificity and are resistant to the acidic conditions found in the stomach or to digestive enzymes of the intestinal tract. These features suggest that VLRB antibodies may be ideally suited to target bacterial pathogens in the gastrointestinal tract. In this research application, we propose to explore the applicability of VLRB antibodies (i) to target pathogenic bacteria and (ii) to target factors of the immune system in response to pathogenic bacteria challenge that promote inflammation. The results from this study will provide information on the suitability of VLRB antibodies as alternative to antibiotic treatment. They will determine the feasibility of VLRB antibody-based targeting of pathogenic bacteria or factors promoting inflammation in the stomach or intestines with the aim to develop VLRB antibodies as novel class of oral therapeutic.
Competitiondate
202509
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ehrhardt, Rudolf A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~